In a clinical trial conducted at Tübingen University Hospital, 20 preterm infants (gestational age ≥ 26 + 0/7) were administered the surfactant Alveofact® (45 mg/ml; Lyomark Pharma, Oberhaching, Germany) using the new LISA application aid, Neofact®. The aim of Neofact® was to enable a simple and gentle method for the administration of surfactant that works without the use of Magill forceps. Neofact® facilitates surfactant administration and is also suitable for any gestational age. This was confirmed by convincing results in the study. An extremely high success rate was achieved (95%), with complications occurring only rarely.
Neofact® was developed by Dr. Christian Maiwald in collaboration with Lyomark Pharma GmbH and MurrPlastik, and is already well-established in clinical practice.
Further information about the study can be found here.